目的 探讨不同剂量阿托伐他汀对颈动脉粥样硬化干预效果。方法 回顾性分析颈动脉粥样硬化患者860例,其中使用阿托伐他汀20 mg治疗的420例(A组),使用10 mg治疗的440例(B组),治疗6个月。在治疗前及治疗后6个月,均经颈动脉超声观察颈动脉内膜中层厚度(intima-media thickness,IMT),测高敏C-反应蛋白(high sensitivity C-reactive protein ,hs-CRP)、血脂的变化。结果 治疗6个月后,两组IMT、hs-CRP、血脂水平较治疗前明显降低(P<0.01);A组较B组IMT、 hs-CRP、血脂水平降低更加显著(P<0.05)。在6个月随访期间,A组心脑血管事件发生率9.6%,B组13.6%,差异无统计学意义(P＞0.05)。结论 阿托伐他汀20 mg对抑制颈动脉粥样硬化的发展,减少心脑血管事件可能更具有优势。
Abstract
Objective To study the effect of different dose atorvastatin on carotid atherosclerosis.Methods Eight hundred and sixty old patients with carotid atherosclerosis were randomized into atorvastatin 20 mg group (group A, n=420) and atorvastatin 10 mg group (group B, n=440) for six months. Intima-media thickness(IMT) of carotid artery, hs-CRP, serum lipids were detected before and after treatment for six months. Results IMT of carotid artery, hs-CRP, serum lipids in group A were reduced significantly after theatment compared with those before treatment, and in group A were reduced significantly compared with group B.Overall incidence of cardio-and cerebrovasular events in group A was 9.6% and in group B was 13.6%.Conclusions Atorvastain 20 mg treatment in delaying and reversing the progression of carotid atherosclerosis,and reducing cardio-and cerebrovascular events is superior to atorvastatin 10 mg treatment.
关键词
颈动脉粥样硬化 /
他汀类降脂药 /
高敏C-反应蛋白 /
颈动脉内膜中层厚度
Key words
carotid atherosclerosis /
antilipidemic agents /
high sensitivity C-reactive protein /
intima-media thickness, carotid artery
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] De Kreutzenberg S V,Tiengo A,Avogaro A. Cerebrovascular disease in diabetes mellitus: The role of carotid intima-media thickness[J].Nutrition,Metabolism and Cardiovascular Disease,2009,19:667-673.
[2] Baigent C,Keech A,Kearney P M,et al. Cholestrol Treatment Trialists, Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trial of statins[J].Lancet,2005,366:1267-1278.
[3] 李 卫,寇继寅,李 彤,等.颈动脉粥样硬化的发生率及其危险因素[J].武警医学,2005,16(3):179-181.
[4] 张文斌,宋莜莜.他汀类药物临床研究进展[J].心血管病学进展,2006,27(1):79-81.
[5] 王继征,张国清,阚国庆,等.阿托伐他汀改善高血压合并2型糖尿病患者颈动脉粥样硬化[J].中华高血压杂志,2006,14(6):789-792.
[6] 程守华,童文玲.强化降脂对老年冠心病患者的疗效及安全性研究[J].武警医学,2010,21(5):527-528.
[7] 傅向华,赵丹华,汪雁博,等.冠状动脉介入术后患者经不同剂量他汀类药物治疗后颈动脉内膜中层厚度的变化与支架内再狭窄的相关性[J].中华心血管病杂志,2011,39:25.
[8] 叶 平,王 节,肖延忠,等. C反应蛋白与动脉粥样硬化形成有关[J].中国动脉硬化杂志,2001,9(2):146-148.
[9] 朱幼玲,朱双根,徐格林,等.脑梗死患者的颈动脉斑块特点及相关危险因素的回归分析[J].中华老年心脑血管病杂志,2009,11(3):686-688.
